Elicio Therapeutics (ELTX) Current Assets (2020 - 2026)

Elicio Therapeutics has reported Current Assets for 7 years, with the latest figure at $16.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 22.62% year-over-year to $16.2 million; the trailing twelve-month figure through Mar 2026 stood at $16.2 million (down 22.62% YoY), and the FY2025 full-year result was $19.3 million, down 6.68% from the prior year.
• Current Assets for Q1 2026 stood at $16.2 million, down from $19.3 million in the prior quarter.
• The five-year high for Current Assets was $76.2 million in Q1 2022, with the low at $6.7 million in Q2 2024.
• Historically, Current Assets has averaged $28.5 million across 5 years, with a median of $20.9 million in 2025.
• Annual changes were most pronounced in 2022 — Current Assets slumped 88.25% — and 2025, when it soared 237.84%.
• Elicio Therapeutics' Current Assets stood at $10.7 million in 2022, then surged by 52.54% to $16.3 million in 2023, then increased by 26.58% to $20.7 million in 2024, then slipped by 6.68% to $19.3 million in 2025, then slipped by 16.11% to $16.2 million in 2026.
• The last three Current Assets figures came in at $16.2 million (Q1 2026), $19.3 million (Q4 2025), and $21.5 million (Q3 2025), per Business Quant data.